
<article class="mb-5" id="ontologyfile">
<content>
<h2>List of Research Studies Utilized</h2>
 <h3> <strong> Pharmacologic Approaches to Glycemic Treatment (Chapter 8) </strong> </h3>
<ol>
<li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1056/NEJMoa0806470&link_type=DOI">10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1210/jc.2015-3754&link_type=DOI">Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1111/j.1463-1326.2009.01060.x&link_type=DOI">Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1111/dom.12438&link_type=DOI">New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-na√Øve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1111/dom.12532&link_type=DOI">Glycaemic control and hypoglycaemia with new insulin glargine300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1615692&link_type=DOI">Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1016/j.pcd.2013.07.005&link_type=DOI">Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study</a></li>

<h3> <strong> Cardiovascular Disease and Risk Management (Chapter 9) </strong> </h3>
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1001286&link_type=DOI">Effects of intensive blood-pressure control in type 2 diabetes mellitus</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1016/S0140-6736(07)61303-8&link_type=DOI">Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1111/j.1524-6175.2004.03216.x&link_type=DOI">Cardiovascular Outcomes Using Doxazosin vs. Chlorthalidone for the Treatment of Hypertension in Older Adults With and Without Glucose Disorders: A Report From the ALLHAT Study</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1056/NEJMoa0801317&link_type=DOI">Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events</a></li>
 
 <li><a href="https://ibm.box.com/s/tkwn426zqf6pthpn8oyuehbr71qx6wvi">Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes</a></li>
 
 <li><a href="https://ibm.box.com/s/r5b7gz3uf8mx0ezi8stejwvrw2kzoyij
">Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1056/NEJM200101043440101&link_type=DOI">Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1303154&link_type=DOI">Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1001/jama.2015.10081&link_type=DOI">Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1093/eurheartj/ehw132&link_type=DOI">A randomized controlled study of Finerenone vs. Eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1056/NEJMoa0805796&link_type=DOI">Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial</a></li>
 
 <li><a href="https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1001282&link_type=DOI">Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus</a></li>
 
 <li><a href="https://ibm.box.com/s/yp0q7anj3relogeecrjh5bl054mz11v4">Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentrer andomised placebo-controlled trial</a></li>
 
 </ol>
 </content>
 </article>

 
 
